Access routes and asking prices - getting drugs to cancer patients 11 Nov 2020 Today the ICR and 15 organisations launch a nine point plan on cancer drug pricing and access. Here, our Policy Officer Joanne Duffy speaks to patient advocate Emma Robertson about the recommendations. Find out more Show/Hide
What’s coming for cancer in the 2020s 23 Jan 2020 We’ve learned a lot about cancer in the last decade, with survival rates better now than ever before. Our Policy Adviser, Roya Ziaie, takes a look at what might be in store over the next ten years in an ever-changing field. Find out more Show/Hide
Making the case for ‘regulatory innovation’ in cancer research 02 Dec 2019 Regulation of new cancer therapies, whilst crucially important, can become a barrier to innovation. Our Policy Adviser, Roya Ziaie, takes a look at the current regulatory landscape and what is needed in the future to ensure innovative treatments find their way to patients as quickly as possible. Find out more Show/Hide
Investing in the future – what does the life sciences sector deal mean for cancer research? 08 Dec 2017
Science after Brexit – how will we continue to collaborate with the EU on medical research? 08 Sep 2017